Followers | 43 |
Posts | 5751 |
Boards Moderated | 0 |
Alias Born | 04/12/2021 |
Wednesday, November 30, 2022 8:51:36 AM
“9:21a ET 3/9/2022 - Benzinga
CNS Pharmaceuticals Addresses Recent Share Price Activity
Video from John Climaco, CEO of CNS Pharmaceuticals now available on the Company's website
HOUSTON, March 9, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released a video to shareholders reiterating its operational and clinical progress for lead product candidate, Berubicin, and addressing recent share price activity.
"The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market â?? both of which are things out of our control. However, as the CEO, what I do have control over is executing on the day-to-day operations, which I want to reiterate and emphasize, have simply never been stronger. We continue to enroll patients around the world in our potentially pivotal study of Berubicin in the treatment of adult GBM. We have the leading minds in the field around the world working on this trial with us and we have encouraging ongoing dialogue with the FDA to ensure that our potentially pivotal trial continues to represent the state-of-the-art in the field. So, while what we cannot control remains to be a point of frustration, we are committed to continuing to execute our operational excellence to drive recognition in the market of Berubicin and what we believe could be its immense potential for patients â?? the key driver for ultimately generating shareholder value and tremendous hope for GBM patients worldwide," commented John Climaco, CEO of CNS Pharmaceuticals. "We put our heads down every day and continue to charge forward in our mission to change the game in glioblastoma via Berubicin."”
my posts are always theory and not financial advice
Recent CNSP News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/09/2024 09:28:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 09:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 10:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:00:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 03:28:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 03:28:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 03:27:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 03:26:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 10:00:18 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/31/2024 09:27:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:01:11 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/22/2024 11:02:51 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/10/2024 10:26:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 02:15:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 01:36:10 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/08/2023 10:28:07 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/30/2023 10:20:11 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/20/2023 10:26:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/18/2023 01:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 12:00:11 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM